このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Viva Biotech Holdings 配当金

配当金基準チェック /06

Viva Biotech Holdings配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	1.3%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-HK$0.054
3年後の配当利回り予想	0%

最近の配当金アップデート

Recent updates

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Jun 19

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 14

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

May 03

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Apr 26

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Jan 19

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 01

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Sep 25

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Jul 11

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Apr 14

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Mar 13

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

Feb 06

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Jan 02

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Nov 21

決済の安定と成長

配当データの取得

安定した配当: 1873の 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: 1873の配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Viva Biotech Holdings 配当利回り対市場

1873 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (1873)	n/a
市場下位25% (HK)	3.4%
市場トップ25% (HK)	7.9%
業界平均 (Life Sciences)	1.3%
3年後のアナリスト予想 (1873)	0%

注目すべき配当: 1873は最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: 1873は最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: 1873の配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: 1873が配当金を報告していないため、配当金の持続可能性を計算できません。

Viva Biotech Holdings 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Viva Biotech Holdings Recommend No Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.01 per share

Viva Biotech Holdings Recommends Final Dividend for the Year Ended December 31, 2020, Payable on or About July 9, 2021

Recent updates

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Viva Biotech Holdings, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)

New minor risk - Share price stability

Viva Biotech Holdings to Report Fiscal Year 2023 Results on Mar 28, 2024

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director

New major risk - Revenue and earnings growth

Viva Biotech Holdings Announces Executive Changes

Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer

New minor risk - Shareholder dilution

First half 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.048 loss in 1H 2022)

Viva Biotech Holdings to Report First Half, 2023 Results on Aug 29, 2023

Viva Biotech Holdings announced that it has received HKD 470 million in funding

Executive VP & Executive Director recently bought HK$226k worth of stock

New minor risk - Share price stability

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Full year 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.15 profit in FY 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Viva Biotech Holdings Announces Board Changes

Investor sentiment improved over the past week

Investor sentiment improved over the past week

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

First half 2022 earnings released: CN¥0.048 loss per share (vs CN¥0.044 profit in 1H 2021)

Viva Biotech Holdings to Report First Half, 2022 Results on Aug 29, 2022

Viva Biotech Holdings Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Full year 2021 earnings: Revenues miss analyst expectations

Viva Biotech Holdings Recommend No Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Viva Biotech Holdings Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2021

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Investor sentiment improved over the past week

Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Executive VP & Executive Director recently bought HK$1.1m worth of stock

First half 2021 earnings released: EPS CN¥0.044 (vs CN¥0.38 loss in 1H 2020)

Insider recently sold HK$345m worth of stock

Executive Director Fengmao Hua has left the company

Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Upcoming dividend of HK$0.01 per share

Viva Biotech Holdings Recommends Final Dividend for the Year Ended December 31, 2020, Payable on or About July 9, 2021

Executive Director & CFO recently sold HK$257m worth of stock

We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Full year 2020 earnings released: CN¥0.25 loss per share (vs CN¥0.19 profit in FY 2019)

Viva Biotech Holdings Provides Earnings Guidance for the Year Ended December 31, 2020

Viva Biotech Holdings to Report Fiscal Year 2020 Results on Mar 30, 2021

Viva Biotech Holdings Reports Loss Guidance for the Year Ended December 31, 2020

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

New 90-day low: HK$6.90

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

New 90-day low: HK$7.27

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Viva Biotech Holdings Announces Resignation of MAO Jun as Non-Executive Director

New 90-day low: HK$7.38

Executive Director & CFO recently bought HK$7.0m worth of stock

New 90-day low: HK$8.18

First half earnings released

配当金基準チェック /06